awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625
Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
P2860
Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48352556-7F0ED03C-490D-4C57-AB75-318E6B150625
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5acfef2b24f0621e221466c253f8bcd1644e8d23
P2860
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati